title: [Efficacy and safety of cyclophosphamide treatment in progressive multiple sclerosis].
abstract: BACKGROUND
  Cyclophosphamide (CPM) is used empirically in the treatment of progressive multiple sclerosis. The purpose of this study was to evaluate its efficacy in naive patients with progressive multiple sclerosis.
  
  
  METHODS
  Thirty-one patients were retrospectively included (17 secondary multiple sclerosis, 14 primary progressive multiple sclerosis), and received infusions of CPM (600mg/m(2)) every eight weeks, for 18 months. Evaluation was based on time to EDSS progress.
  
  
  RESULTS
  Among patients with secondary progressive multiple sclerosis, 94% were stable or improved at six months, 77% at 12 months, and 75% at 18 months. The same result was reported in 69.2% of primary progressive multiple sclerosis at six months, 64% at 12 months, and 55.5% at 18 months. We found no difference between the two groups.
  
  
  CONCLUSIONS
  Our results suggest that the CPM is efficient in progressive multiple sclerosis; however, its place must be reconsidered before establishing an international consensus for treatment; open label studies are needed to validate the present findings.
authors.affiliation: Service de neurologie B et neurogénétique, hôpital des spécialités, Rabat, Maroc. elaitbenha@yahoo.fr
authors.forename: E
authors.initials: E
authors.lastname: Ait Ben Haddou
authors.forename: A
authors.initials: A
authors.lastname: Benomar
authors.forename: S
authors.initials: S
authors.lastname: Ahid
authors.forename: H
authors.initials: H
authors.lastname: Chatri
authors.forename: C
authors.initials: C
authors.lastname: Slimani
authors.forename: M
authors.initials: M
authors.lastname: Hassani
authors.forename: K
authors.initials: K
authors.lastname: El Alaoui Taoussi
authors.forename: R
authors.initials: R
authors.lastname: Abouqal
authors.forename: M
authors.initials: M
authors.lastname: Yahyaoui
mesh_terms: D000328:Adult; D017668:Age of Onset; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D006233:Persons with Disabilities / Q000706:statistics & numerical data; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D012189:Retrospective Studies; D012449:Safety; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D003520:Cyclophosphamide